Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 63682931

Next Previous
Drug Profile

JNJ 63682931

Alternative Names: Ad26.HPV18; HPV18 Ad26-vectored vaccine; JNJ-63682931

Latest Information Update: 11 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Vaccines and Prevention B.V
  • Developer Bavarian Nordic; Janssen Vaccines and Prevention B.V
  • Class Antivirals; Papillomavirus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Human papillomavirus infections

Most Recent Events

  • 15 Oct 2020 Janssen Vaccines & Prevention terminates phase I/II trial in Human papillomavirus infections in Belgium and USA due to low enrolment and increasing COVID restrictions (IM) (NCT03610581)
  • 27 Sep 2018 Phase-I/II clinical trials in Human papillomavirus infections in USA (IM) (NCT03610581)
  • 03 Aug 2018 Janssen Vaccines & Prevention and Bavarian Nordic plans a first-in-man phase I/IIa trial for Human papillomavirus infections (Combination therapy) in USA in August 2018 (NCT03610581) (EudraCT2018-000200-41)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top